Generate Biomedicines, Inc. GENB
Set alert
At close · Oct 30
After hours · Oct 30, 5:34 PM ET
- YTD
- +14.31%
- 1 year
- +14.31%
- Open
- 14.80
- Prev close
- 15.77
- Mkt cap
- 1.86B
- Vol
- 1.17M
- Avg vol
- 1.17M
- EPS
- -2.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.25
- High
- 15.63
- Forward P/E
- -6.39
- Beta
- 0.00
- Short ratio
- 7.37
- Inst. own
- 79.13%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 15.03
- 200-d avg
- 14.07
- 1y target
- 27.00
5D chart
Signals (97)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 11:10 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:25 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:20 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
News
1 week ago globenewswire.com
Generate Biomedicines to Participate in November Investor Conferences
SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…
2 weeks ago defenseworld.net
Banque Pictet & Cie SA Buys New Position in Generate Biomedicines Inc $GENB
Banque Pictet and Cie SA purchased a new stake in Generate Biomedicines Inc (NASDAQ: GENB) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).…
2 weeks ago benzinga.com
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Generate Biomedicines & Zealand Pharma team up to develop AI-engineered protein therapies for obesity & metabolic diseases.
-
2 weeks ago benzinga.com
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration
Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a multi-target strategic collaboration with Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology company transforming the future of…
2 weeks ago globenewswire.com
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases…
2 weeks ago globenewswire.com
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
2 weeks ago seekingalpha.com
Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm
Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing and broad phenotype efficacy. GENB leads the TSLP antagonist race with two…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
4 weeks ago defenseworld.net
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)
Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
-
1 month ago benzinga.com
Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell Therapy
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trialsFirst patient treated in new clinical…
1 month ago globenewswire.com
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical…
1 month ago defenseworld.net
Squarepoint Ops LLC Makes New $530,000 Investment in Generate Biomedicines Inc $GENB
Squarepoint Ops LLC bought a new position in Generate Biomedicines Inc (NASDAQ: GENB) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
1 month ago seekingalpha.com
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
1 month ago globenewswire.com
Generate Biomedicines Inc. to Participate in September Investor Conferences
SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…
2 months ago benzinga.com
Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
2 months ago proactiveinvestors.com
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends…
2 months ago proactiveinvestors.com
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO...
-
2 months ago benzinga.com
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of…
2 months ago globenewswire.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be…
2 months ago fool.com
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen.
3 months ago fool.com
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful…
4 months ago benzinga.com
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.
4 months ago benzinga.com
Why Constellation Brands Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Constellation Brands (NYSE: STZ) rose in pre-market trading after reporting strong Q1 earnings and raising its FY27 guidance. Other gainers include DXF, EHGO, JEM, TC, VMAR, LGPS, BTOG, LUNR, and BE.…
4 months ago prnewswire.com
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced…
5 months ago fool.com
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
5 months ago prnewswire.com
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday,…
-
5 months ago benzinga.com
Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22
Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and raises the price target from $20 to $22.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $16 to $25.
-
5 months ago benzinga.com
Generate Biomedicines Q1 EPS $(1.07) Misses $(0.54) Estimate, Sales $7.224M Beat $5.938M Estimate
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.54) by 98.15 percent. This is a 33.95 percent increase over…
5 months ago prnewswire.com
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in…
6 months ago benzinga.com
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed outlook on top names. Check our analyst ratings page for upgrades, downgrades, initiations. See opinions on CRDO.
-
6 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $16
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $16.
-
7 months ago benzinga.com
Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26
Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.
-
7 months ago benzinga.com
Morgan Stanley Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $20
Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $20.
-
7 months ago benzinga.com
Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24
Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $24.
-
7 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Generate Biomedicines with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating.
7 months ago benzinga.com
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. KBH, SOLV, SDHC, GENB coverage initiated.
-
7 months ago benzinga.com
Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30
Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.
8 months ago benzinga.com
Preview: Generate Biomedicines, Inc Set To IPO Tomorrow
Preview: Generate Biomedicines, Inc Set To IPO Tomorrow